Protective‑allele lists enable enhancement markets

Publishing curated lists of 'protective' or 'enhancing' human alleles (with effects and caveats) turns technical knowledge into a de facto product roadmap: fertility clinics, embryo‑selection services, gene‑therapy developers and consumer genomics firms can use the list to build offerings or prioritize edits. That process simultaneously lowers technical uncertainty and reframes certain genetic variants from rare curiosities into legible, purchasable interventions. — This matters because it makes explicit the pathway from academic catalogues to commercial reproductive choices, raising regulatory, equity and biosecurity issues that policymakers and the public must confront now.